Pharma Figures 2024 - The Belgian biopharmaceutical sector under pressure

The latest Pharma Figures raise concerns. It is clear that we are no longer dealing with the familiar "business as usual" situation we have seen in recent years, marked by steady growth and positive trends in employment, patent applications, and exports. 
In the context of the current geopolitical situation, it is becoming increasingly evident that Belgium, and Europe in general, must rethink its strategy.
That is why we are calling for a robust Life Sciences strategy to strengthen Europe’s competitive position: one that better valorises innovation, removes obstacles to innovative activity, and boosts investment in both our domestic market and the development of new markets.
If not, we risk losing the biopharmaceutical sector as a pillar of the manufacturing industry in our country.